Obecabatagene autoleucel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Obecabatagene autoleucel Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
10
Registered trials
37
Result records
2
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Obecabatagene autoleucel can convert its Autologous CAR-T profile and CD19 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Obecabatagene autoleucel (query alias: Obecabatagene autoleucel) |
|---|---|
| Modality / target | Autologous CAR-T; CD19; CD19 modulators, Immunostimulants, T lymphocyte replacements |
| Highest global status | Approved |
| Originator | University College London |
| Active developers | AGC Biologics A/S, Autolus Ltd., Autolus Therapeutics Plc |
The MCP disease footprint includes Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07400029 | Phase 2 | Recruiting | 40 | relapse free survival (RFS) (Cohort A) |
| NCT07053800 | Phase 2 | Recruiting | 35 | Proportion of participants who achieve complete renal response (CRR) |
| NCT07053059 | Phase 2 | Recruiting | 30 | Safety and Adverse Events (AEs) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
LUMINA: A PHASE II TRIAL IN PROGRESS EVALUATING THE SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL IN SEVERE, REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS WITH ACTIVE LUPUS NEPHRITIS
Phase 2; n=35; evaluation: Positive. Reported fields: CRR(6-month) = 60.0 %
OBECABTAGENE AUTOLEUCEL (obe-cel), A CD19-TARGETING CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN PATIENTS WITH SEVERE, REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (srSLE): INITIAL SAFETY, PRELIMINARY EFFICACY, PHARMACOKINETICS, AND BIOMARKER RESULTS FROM THE PHASE I CARLYSLE STUDY
Phase 1; n=13; evaluation: Positive. Reported fields: DLT = One case of liver injury was observed, which fully resolved. This was possibly related to CAR T-cell activity or concomitant medication-related toxicity (anti-infective prophylaxis) and was therefore considered a DLT. ; DLT = One case of liver injury was observed, which fully resolved. This was possibly related to CAR T-cell activity or concomitant medication-related toxicity (anti-infective prophylaxis) and was therefore considered a DLT.
The effect of obecabtagene autoleucel (obe-cel) on adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and extramedullary disease (EMD).
Phase 1/2; n=127; evaluation: Positive. Reported fields: AE(Grade ≥3) = cytokine release syndrome in pts with and those w/o EMD was 3.7% and 2.0%; the incidence of Grade ≥3 immune effector cell-associated neurotoxicity syndrome was 19% and 4.0%, respectively. ; AE(Grade ≥3) = cytokine release syndrome in pts with and those w/o EMD was 3.7% and 2.0%; the incidence of Grade ≥3 immune effector cell-associated neurotoxicity syndrome was 19% and 4.0%, respectively.
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Obecabatagene autoleucel addresses Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Autologous CAR-T—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-02-08 | BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs | Phase 1/2 | Financial terms not disclosed |
| 2018-04-23 | Autolus announces license agreement with UCL Business PLC for clinical-stage product candidate in development for the treatment of B-cell malignancies | Phase 1 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Chimeric Antigen Receptor (CAR) Comprising a CD19-Binding Domain”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
